Clinical Trials Sponsored by Zai Lab (Shanghai) Co., Ltd.

Total 1452 results

Zai Lab (Shanghai) Co., Ltd.

Active, not recruiting

Clinical Trial Evaluating the Efficacy and Safety of ZL-2306 (Niraparib) in Ovarian Cancer Patient

Platinum-sensitive Relapsed Ovarian Cancer

China
Zai Lab (Shanghai) Co., Ltd.

Completed

A Study to Assess the Efficacy and Safety of DCC-2618 and Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumors After Treatment With Imatinib

Gastrointestinal Stromal Tumor(GIST)

China
Zai Lab (Shanghai) Co., Ltd.

Terminated

MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients

Advanced Hepatocellular Carcinoma (HCC)

China
Zai Lab (Shanghai) Co., Ltd.

Terminated

A Study to Evaluate the Safety and Efficacy of MGD013 in Patients With Melanoma

Unresectable, Recurrent or Metastatic Melanoma | Untreated Mucosal or Acral Lentiginous Melanoma

China
Zai Lab (Shanghai) Co., Ltd.

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC

Breast Cancer Metastatic

Taiwan
Zai Lab (Shanghai) Co., Ltd.

Completed

A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)

Gastrointestinal Stromal Tumors

China
Zai Lab (Shanghai) Co., Ltd.

Completed

A Study of Niraparib in Patients With Relapsed Ovarian Cancer

Ovarian Cancer

China
Zai Lab (Shanghai) Co., Ltd.

Completed

To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malignancies

Solid Malignancies

China
Zai Lab (Shanghai) Co., Ltd.

Completed

A Trial of ZL-1201 in Subjects With Advanced Cancer

Advanced Cancer

United States, China
Zai Lab (Shanghai) Co., Ltd.

Terminated

A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment

Gastric Cancer | Triple Negative Breast Cancer | Endometrial Carcinoma | Biliary Tract Carcinoma

China
Zai Lab (Shanghai) Co., Ltd.

Completed

A Study to Evaluate the Pharmacokinetics of Margetuximab in Chinese Patients With HER2+ MBC

HER2 Positive Metastatic Breast Cancer

China
Zai Lab (Shanghai) Co., Ltd.

Active, not recruiting

A Study of ZL-2306 (Niraparib) as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer

Ovarian Cancer

China
Zai Lab (Shanghai) Co., Ltd.

Terminated

A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer

Extensive-stage Small Cell Lung Cancer

China
Zai Lab (Shanghai) Co., Ltd.

Completed

A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC

Hepatocellular Carcinoma (HCC)

China
Zai Lab (Shanghai) Co., Ltd.

Completed

The Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of ZL-2306 (Niraparib) in Patients With Ovarian Cancer

Ovarian Cancer

China
argenx
Zai Lab (Shanghai) Co., Ltd.

Recruiting

A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis (ZL-1103-013)

Lupus Nephritis

China
MacroGenics
Zai Lab (Shanghai) Co., Ltd.

Active, not recruiting

Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer (MAHOGANY)

Gastric Cancer | Gastroesophageal Junction Cancer | HER2-positive Gastric Cancer

Korea, Republic of, United States, China, Italy, Taiwan, Germany, Singapore, United Kingdom, Poland
Zai Lab (Shanghai) Co., Ltd.
Zai Lab (US) LLC

Recruiting

An Open-label, Multicenter Study of ZL-1310 in Subjects With Small Cell Lung Cancer

SCLC

United States
Karuna Therapeutics
Zai Lab (Shanghai) Co., Ltd.

Recruiting

A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 Schizophrenia (UNITE-001)

Schizophrenia

China
Incyte Corporation
Zai Lab (Shanghai) Co., Ltd.

Active, not recruiting

Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer (POD1UM-304)

Metastatic Squamous Non-Small Cell Lung Cancer | Metastatic Nonsquamous Non-Small Cell Lung Cancer

China, Czechia, Russian Federation, Serbia, Malaysia, Vietnam, United States, Poland, Ukraine, Romania, Turkey, Brazil, Bulgaria, Georgia, Hungary, Philippines, South Africa
Zai Lab (Shanghai) Co., Ltd.
Mirati Therapeutics Inc.

Active, not recruiting

The Clinical Trial to Evaluate the Pharmacokinetics and Safety of MRTX849 in Patients With Advanced Solid Tumors

Advanced or Metastatic Solid Tumor

China
NovoCure GmbH
Zai Lab (Shanghai) Co., Ltd.

Unknown

Effect of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Chemotherapy as First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma

Gastric Cancer | GastroEsophageal Cancer

Hong Kong
Bristol-Myers Squibb
Zai Lab (Shanghai) Co., Ltd.

Recruiting

A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

Carcinoma, Non-Small-Cell Lung

Japan, China, Spain, Germany, Korea, Republic of, Austria, Brazil, Romania, France, United States, Italy, Argentina, Canada, Chile, Greece, Hungary, India, Poland, Turkey, Switzerland, Netherlands
Turning Point Therapeutics, Inc.
Zai Lab (Shanghai) Co., Ltd.

Recruiting

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)

Locally Advanced Solid Tumors | Metastatic Solid Tumors

United States, China, Japan, Australia, Belgium, Canada, Denmark, France, Germany, Hong Kong, Hungary, Italy, Korea, Democratic People's Republic of, Korea, Republic of, Netherlands, Poland, Singapore, Spain, Taiwan, United Kingdom
Five Prime Therapeutics, Inc.
Zai Lab (Shanghai) Co., Ltd.

Completed

A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer (FIGHT)

Gastric Cancer

United States, Spain, China, Italy, Korea, Republic of, Portugal, Taiwan, Japan, Turkey, France, Hungary, Thailand, Germany, Poland, Australia, Belgium, Romania, United Kingdom
Zai Lab (Hong Kong), Ltd.
Merck Sharp & Dohme LLC; Zai Biopharmaceutical (Shanghai) Co., Ltd.

Recruiting

A Phase 1 Study of ZL-1218 in Subjects With Advanced Solid Tumors

Malignant Solid Tumor

United States, Spain
Zai Biopharmaceutical (Suzhou) Co., Ltd.

Recruiting

A Study of ZL-1211 in Patients With Advanced Solid Tumor

Advanced Solid Tumor

United States, China
Peking Union Medical College Hospital
Zai Lab (Shanghai) Co., Ltd.

Unknown

Efficacy and Safety of Niraparib Combined With Oral Etoposide in Platinum Resistant/Refractory Recurrent Ovarian Cancer

Ovarian Cancer

China
Peking Union Medical College Hospital
Zai Lab (Shanghai) Co., Ltd.

Not yet recruiting

A Phase II Trial to Explore Niraparib and Anlotinib Maintenance Retreatment in Platinum-Sensitive Recurrent Ovarian Cancer Patients Previously Treated With PARPi (t)

Epithelial Ovarian Cancer
Zai Lab Pty. Ltd.

Unknown

Study of the Tolerability and Pharmacokinetic of ZL-2102 With an Investigation of Food Effect in Healthy Male Subjects

Chronic Obstructive Pulmonary Disease | Asthma | Idiopathic Pulmonary Fibrosis

Australia
Zai Lab Pty. Ltd.

Completed

Study to Evaluate the Efficacy and Safety of ZL-3101 in Subjects With Subacute Eczema

Eczema

China
Zai Lab (Hong Kong), Ltd.
Zai Lab (US) LLC

Not yet recruiting

A Phase 2 Study of ZL-1102 in Patients With Chronic Plaque Psoriasis

Plaque Psoriasis

Australia, Canada
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Zai Lab (Shanghai) Co., Ltd.; Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Anlotinib Combined With Niraparib Dual Therapy in Platinum-resistant Recurrent Ovarian Clear Cell Carcinoma. (CC-ANNIE)

Platinum-resistant Recurrent Clear Cell Ovarian Cancer

China
Zai Lab (Hong Kong), Ltd.

Recruiting

A Phase 3b Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline to Moxifloxacin for Treating Adult Subjects With CABP (public)

Community-acquired Bacterial Pneumonia

United States
argenx
Zai Lab Pty. Ltd.

Recruiting

A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Primary Membranous Nephropathy (ZL-1103-014)

Membranous Nephropathy

China
InxMed (Shanghai) Co., Ltd.
InventisBio Co., Ltd

Recruiting

a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors

Solid Tumor

China
InventisBio Co., Ltd
InxMed (Shanghai) Co., Ltd.

Recruiting

Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors

Solid Tumor

China
Shanghai YingLi Pharmaceutical Co. Ltd.
Shanghai HyaMab Biotech Co.,Ltd.

Not yet recruiting

A Phase Ib/II Clinical Trial of PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor

Advanced Solid Tumors
Shanghai SIMRD Biotechnology Co., Ltd.

Completed

The Pharmacokinetics (PK), Pharmacodynamics(PD), Safety, Tolerability of SR1375 in Healthy Volunteers

Healthy

China
Shanghai SIMRD Biotechnology Co., Ltd.

Completed

The Pharmacokinetics (PK), Safety, Tolerability of SR419 in Healthy Volunteers

Healthy

China
InxMed (Shanghai) Co., Ltd.

Not yet recruiting

IN10018 Combination Therapy in Previously-treated Solid Tumors

Solid Tumor
InxMed (Shanghai) Co., Ltd.

Active, not recruiting

IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients

Locally Advanced or Metastatic Solid Tumors

China
Shanghai GeneChem Co., Ltd.

Unknown

A Study of Mesothelin Redirected Autologous T Cells for Advanced Pancreatic Carcinoma (meso-CART)

Pancreatic Cancer

China
Convalife (Shanghai) Co., Ltd.

Not yet recruiting

Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastases

Her2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastasis
Convalife (Shanghai) Co., Ltd.

Not yet recruiting

CVL237 Tablets for APDS/PASLI

PI3K and P110delta Hyperactivation Syndrome

China
Convalife (Shanghai) Co., Ltd.

Not yet recruiting

Neratinib Tablets in the Treatment of Advanced NSCLC With Rare EGFR Mutations (CVL009-2001)

NSCLC

China
InxMed (Shanghai) Co., Ltd.

Recruiting

IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer

Ovarian Cancer Recurrent

China
InxMed (Shanghai) Co., Ltd.

Recruiting

IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC

NSCLC

China
InxMed (Shanghai) Co., Ltd.

Recruiting

IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer

Platinum-resistant Ovarian Cancer

China
InxMed (Shanghai) Co., Ltd.

Recruiting

IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma

Metastatic Melanoma

United States, Australia

Clinical Trials Sponsored by Zai Lab (Shanghai) Co., Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mongolia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations